| Product Name |
Anti-EGFRvIII Monoclonal Antibody, Recombinant |
| Catalog # |
EG-369 |
| Size |
100 µg |
| Key Features |
- Rabbit monoclonal antibody produced in HEK293 cells under serum-free, protein-free conditions
- Purified by Protein A affinity chromatography
- High batch-to-batch consistency and reproducibility
- Long-term supply security
|
| Clone Number |
R6 |
| Immunogen |
Proprietary peptide |
| Target |
Human EGFRvIII mutant |
| Species Cross-Reactivity |
Human |
| Applications |
Flow Cytometry, Immunoprecipitation (IP), ELISA, Western Blot |
| Recommended Working Concentrations |
- Flow Cytometry / ELISA: 5 µg/mL final concentration
- Immunoprecipitation: 10 µg per 0.3–0.5 mg cell lysate
- Western Blot: 1 µg/mL final concentration
|
| Background |
Epidermal growth factor receptor variant III (EGFRvIII) is the most common EGFR mutation, present in up to 30% of high-grade gliomas, particularly glioblastoma multiforme (GBM). EGFRvIII is a cancer-specific deletion mutant, restrictively expressed in glioblastoma and some lung cancers, and is not detected in normal tissues. EGFRvIII plays a critical role in tumorigenesis, disease progression, and metastasis, and is recognized as a cancer driver mutation in glioblastoma. Its expression is associated with poor prognosis, making EGFRvIII an ideal target for immunotherapy.
References:
1. Yang J., et al. Cancer Lett. 2017;403:224-30.
2. Jungbluth A.A., et al. PNAS. 2003;100:639-644.
|
| Quality Control |
Fig. A: Flow cytometry assay demonstrating cell binding specificity. U87 cells (EGFRvIII negative), U87 (EGFR++), and U87 (EGFRvIII++) cells were stained with 5 µg antibody in 1 mL PBS containing 5% BSA. Binding was detected with a Cy5-conjugated goat anti-rabbit antibody. Shaded area: isotype control; red line: EGFRvIII antibody staining.
Fig. B: ELISA assay demonstrating target specificity. Recombinant EGFR-hFc (negative control), EGFRvIII-hFc (target), and BSA were immobilized at 5 µg/mL. Biotinylated antibody (1:2 serial dilutions from 200 nM) was incubated at 37 °C for 30 min. Binding was visualized with HRP-conjugated streptavidin.
|
| Concentration |
As indicated on the vial label |
| Formulation |
80% PBS, pH 7.4; 20% glycerol; 5% trehalose; 0.04% sodium azide (preservative) |
| Shipping |
Shipped on blue ice |
| Storage |
Store at -20 to -70 °C (long-term), or at 4 °C for up to one week.
For frequent use, aliquot to avoid repeated freeze-thaw cycles.
|